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In March 2012, American Society for
Reproductive Medicine (ASRM) and
European Society of Human Repro-
duction and Embryology (ESHRE)
held their ﬁrst joint meeting with
the theme of Best Practices in Repro-
ductive Medicine. The goal was to as-
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healthcare. Faculty from both ASRM
and ESHRE presented speciﬁc topics,
focusing on different approaches and
points of view in a wide range of
areas of importance for reproductive
health. This 3-day workshop was
comprised of ‘back-to-back’ sessionsshed online October 24, 2012.
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.1016/j.fertnstert.2012.07.1164where different topics were presented
from both the American and Euro-
pean points of view, debates
where two experts discussed more
controversial issues and several ‘cut-
ting-edge’ lectures. What follows is
a summary of the major themes of
the workshop, divided into sections
rather than speciﬁcally reporting on
the way in which they were presented.
The summaries found below do not
constitute the ofﬁcial positions of
either ASRM or ESHRE. The list of
the presenters may be found at the
end of the review.
REPRODUCTIVE
ENDOCRINOLOGY
This section focused on current con-
cepts and approaches to ovarian
stimulation, particularly for IVF, the di-
agnosis and management of polycysticVOL. 98 NO. 6 / DECEMBER 2012
Fertility and Sterility®ovary syndrome (PCOS) and the poor response to ovarian
stimulation.
Ovarian Stimulation
How to best carry out ovarian stimulation for IVF was a topic of
debate. It was stated that there are several advantages to using
conventional ovulation induction including: (i) cycle program-
ming to optimize IVF clinic efﬁciency, (ii) achieving the highest
success rate from the fewest number of IVF cycles, (iii) creating
a larger number of embryos from which the ‘best’ embryos can
be transferred and (iv) allowing spare embryos to be cryopre-
served in order to have several potential transfer cycles. How-
ever, some disadvantages have to be considered, such as
reduced quality and viability of some oocytes, the increased
burden of treatment and potential complications, higher costs
and the possibility of negative clinical outcomes. The efﬁciency
of oocyte utilization after controlled ovarian stimulation for IVF
has been shown to be poor (25.1 oocytes needed per live birth
and 6–16 retrieved oocytes required for women <38 years;
Inge et al., 2005). In addition, a high oocyte yield has been as-
sociated with an increased aneuploidy rate (51% in women
<35 years having more than 10 oocytes retrieved, compared
with 35% when there were 6–10 oocytes; Haaf et al., 2009).
More recently, what has been considered to constitute
a successful IVF treatment has moved away from the outcome
of a single cycle toward the concept of the singleton birth rate
per initiated cycle over a given time period, including patient
distress, complications and costs (Heijnen et al., 2004). In
view of these considerations, milder stimulation protocols
have been proposed, which are more ‘patient-friendly’ caus-
ing less stress and side effects and reducing costs.
Mild ovarian stimulation is deﬁned as the administration
of ﬁxed, low doses of gonadotrophins in GnRH antagonist cy-
cles and/or the use of anti-estrogens or aromatase inhibitors
with the aim of limiting the outcome to no more than eight
oocytes retrieved (Baart et al., 2007; Nargund et al., 2007).
The combination of mild stimulation protocols with elec-
tive single embryo transfer (eSET) may provide the same de-
livery rate per treatment cycle by reducing the negative
aspects of a more aggressive stimulation. It has been reported
that over 1 year of treatment, the cumulative live birth rates
are similar for mild ovarian stimulation with single embryos
transferred compared with the standard stimulation and two
embryos transferred. A milder IVF treatment protocol also re-
duces the multiple pregnancy rate and overall costs (Heijnen
et al., 2007).
A recent meta-analysis showed that 150 IU/day of rec
FSH in normal responders <39 years is the optimal daily
dose for the best balance between a high pregnancy rate
and a low risk of complications, thus maximizing the cost-
effectiveness of an ART cycle (Sterrenburg et al., 2011). Al-
though evidence in favor of milder ovarian stimulation for
IVF is accumulating, it also has been argued that this protocol
is associated with lower ongoing pregnancy rates and higher
cancelation rates (Hohmann et al., 2003; Heijnen et al., 2007).
In the USA, where cycle-speciﬁc data are reported to the So-
ciety for Assisted Reproductive Technology (SART), reporting
a lower pregnancy rate using a mild stimulation would not be
acceptable in a competitive marketplace. Further, the conceptVOL. 98 NO. 6 / DECEMBER 2012of reporting cumulative pregnancy rates is not acceptable to
most couples who have to pay out of pocket for all treatment.
Ten years after the introduction of mild ovarian stimula-
tion, there is still room for improvement. A more patient-
tailored stimulation should take into account several factors
such as age, BMI, smoking status, the status of ovarian reserve
markers such as anti-Mullerian hormone (AMH) and antral
follicle counts (AFCs; Fauser et al., 2010). With such an ap-
proach, mild stimulation may be an attractive option for
both good and poor responders.
Polycystic Ovarian Syndrome
The two lectures on PCOS were focused on the different def-
initions of PCOS and a review of evidence-based treatment. Of
the three deﬁnitions of PCOS, the one suggested by NIH, as
well as the deﬁnition put forward by the Androgen Excess
and PCOS Society, includes the presence of hyperandrogen-
ism as a required criterion. The Rotterdam deﬁnition
(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group, 2004) is the most widely used and allows
for several possible phenotypes, being deﬁned by two of three
of the following criteria: menstrual irregularity, polycystic
ovaries on ultrasound and hyperandrogenism. Thus, it is pos-
sible for PCOS to be diagnosed in the absence of documented
hyperandrogenism. Although controversial, the importance
and requirement of hyperandrogenism in the deﬁnition was
the position taken by one of the speakers for the following
reasons: it is the most prominent diagnostic feature, it is
most associated with the metabolic features of the disorder,
it serves as a prognostic feature of treatment outcomes and
having hyperandrogenism may be used as a criterion for in-
clusion of these women into multicenter trials studying PCOS.
The Thessaloniki consensus meeting focused on the treat-
ment of PCOS (Thessaloniki ESHRE/ASRM Sponsored PCOS
Consensus Workshop Group, 2008). It was agreed that prior
to initiation of any intervention, emphasis should be given
to the importance of lifestyle management, especially weight
reduction. The recommended ﬁrst-line treatment for ovula-
tion induction remains the anti-estrogen clomifene citrate
(CC). The use of aromatase inhibitors for routine ovulation in-
duction seems to be as effective as CC, but insufﬁcient evi-
dence is currently available on its efﬁcacy and safety
(Requena et al., 2008). Metformin alone is less effective
than CC in inducing ovulation in women with PCOS. The ad-
dition of metformin to CC may be indicated in speciﬁc sub-
groups of women with PCOS, but its use should be restricted
to women with glucose intolerance (Legro et al., 2007;
Thessaloniki ESHRE/ASRM Sponsored PCOS Consensus
Workshop Group, 2008). Based on recent data in the litera-
ture, the routine use of this drug in ovulation induction is
not recommended (Thessaloniki ESHRE/ASRM Sponsored
PCOS Consensus Workshop Group, 2008).
In cases of failure of ovulation or no pregnancy, the pro-
posed second-line intervention includes either exogenous go-
nadotrophins or laparoscopic ovarian surgery (LOS).
The use of exogenous gonadotrophins is reported to be
highly effective, but it is associated with increased chances
for multiple pregnancies and, therefore, careful monitoring of
ovarian response is needed. LOS alone is usually as effective1381
ASRM PAGESas gonadotrophins for ovulation induction and achievement of
pregnancy, but is associated with a signiﬁcantly lower risk of
multiple pregnancy (in one RCT: odds ratio, 0.11; 95% conﬁ-
dence interval, 0.01–0.86; Bayram et al., 2004).
Recommended third-line treatment is IVF. Speciﬁc
patient-tailored approaches for ovulation induction should
be based on initial screening characteristics of the patient.
IVF appears to be a reasonable option, as the risk of multiple
pregnancies can be controlled by SET. Nevertheless, even sin-
gleton pregnancies in women with the classic features of
PCOS are associated with increased health risks, for both
the mother and the fetus (Thessaloniki ESHRE/ASRM
Sponsored PCOS Consensus Workshop Group, 2008).
Poor Ovarian Response
In a retrospective analysis, the performance of women with
a poor ovarian response (POR) was evaluated. POR in a single
cycle with conventional stimulation was deﬁned as one
which was canceled because there were less than three
growing follicles or from which three or less oocytes were
retrieved in response to conventional stimulation. With
these criteria, it was found that the majority of patients,
up to an age of 40 years, exhibited a normal response in
a subsequent stimulation cycle with higher doses of gonad-
otrophins leading to a cumulative ongoing pregnancy rate
that was not different compared with normal responders
(Ferraretti et al., 2010). It was noted that after two consecu-
tive cycles with POR, the risk of POR in further cycles was
close to 100% with a cumulative ongoing pregnancy rate
signiﬁcantly lower than normal responders.
In an attempt to assess ovarian reserve before starting
stimulation, several tests have been proposed. Generally,
ovarian reserve testing (ORT) has moderate accuracy in pre-
dicting quantitative responses but low accuracy for qualita-
tive predictions, unless very high thresholds are used. The
AFC and AMH appear to have the best sensitivity and speci-
ﬁcity (Hendriks et al., 2005; Broer et al., 2009), but even the
best ORT is associated with a 20–25% false-positive rate.
The use of more than one test does not lead to signiﬁcant
improvement.
Several risk factors have been postulated to have a role in
determining POR (Younis, 2011), the most relevant being age,
genetic factors related to premature ovarian ageing, previous
ovarian surgery and chemotherapy/radiotherapy. Possibly,
chronic smoking, pelvic infection, short menstrual cycle
length and endometriomas could also be involved.
There are no data on the quality of the oocytes generated
in POR cycles, but alterations in oocyte quality inﬂuencing
the prospects of pregnancy is likely to be involved in some
cases (Oudendijk et al., 2012).
Most of the treatments proposed to improve the clinical
outcome in women with POR are not supported by sufﬁcient
evidence to be recommended with the possible exception of
the addition of growth hormone, as well as performing em-
bryo transfer on Day 2 versus Day 3 (Kyrou et al., 2009). Sim-
ilarly, no indication seems to favor any particular
intervention either for down-regulation, ovarian stimulation
or adjuvant therapy (Pandian et al., 2010; Musters et al.,
2012). Evaluation of the results yielded by different clinical1382trials is confounded by the heterogeneous deﬁnition of POR.
Thus, patient selection alone might have altered any true ef-
fect of some interventions (Polyzos and Devroey, 2011).
A recent consensus meeting sought to ﬁnd an appropriate
deﬁnition for POR. It concluded that at least two of the follow-
ing features must be present: (i) advanced maternal age or any
other risk factor for POR, (ii) documented POR in a previous
stimulation and (iii) an abnormal ORT (Ferraretti et al., 2011).
In addition, two episodes of POR after conventional stimulation
are sufﬁcient to deﬁne a patient as a poor responder even in the
absence of advanced maternal age or abnormal ORT (Ferraretti
et al., 2011). Patientswith a risk factor for PORandanabnormal
ORT might be classiﬁed as an ‘expected poor responder’, since
they have not undergone a stimulated cycle.EVALUATION AND TREATMENT OF THE
INFERTILE FEMALE
Discussed in some detail was: the role the clinician plays as
a member of the IVF team, newer surgical techniques and
the management of endometriosis.
Role of the Clinician
It was emphasized here that the clinician of the IVF team has
an important role in assuring that an adequate work up has
been carried out, which otherwise might affect outcomes.
Multiple studies have identiﬁed that between 26 and 50%
of patients who fail IVF have uterine abnormalities, suggest-
ing that hysteroscopy could serve as a prognostic factor for
the IVF outcome, especially in the case of ﬁbroids which dis-
tort the endometrial cavity (Bozdag et al., 2008; Sunkara
et al., 2010). Speciﬁc hysteroscopic interventions have been
reported to signiﬁcantly improve the pregnancy rate
(Demirol and Gurgan, 2004).
The presence of hydrosalpinges also has a negative effect
on the ART outcome, and surgery has been shown to improve
pregnancy rates (Johnson et al., 2010).
The testing of ovarian reserve performed on Day 2/3, in-
cluding FSH and E2 levels, should be used for determining an
age-adjusted initial stimulation protocol and not to exclude
treatment. Moreover, being aware that the best markers of
ovarian reserve, AMH and AFC, have limited value in predict-
ing ‘non-pregnancy’; these markers therefore should not be
used to exclude treatment.
New Surgical Techniques
Laparoscopic surgery in Gynecology is widely used, but re-
quires a steep learning curve and deals with long instruments
that impose ﬁxed entry points, different tactile sensations and
a 2D image. Robotics have been proposed to improve surgical
skills through technology, thus overcoming the limitations of
human performance. However, no RCTs are available on the
application of robotics, and we only have comparative obser-
vational studies reporting that it facilitates laparoscopic sur-
gery, shortens operating time and hospital stay, resulting in
less major complications while providing comparable results
(Caillet et al., 2010; Ercoli et al., 2012).
The new approach in laparoscopy is to decrease both the
number of access ports and their size to avoid scars. Therefore,VOL. 98 NO. 6 / DECEMBER 2012
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(single incision laparoscopic surgery), SPA (single port ac-
cess), LESS (endoscopic single site surgery), NOTES (natural
oriﬁce transluminal endoscopic surgery), NOTUS (natural
oriﬁce transumbilical surgery) and TUES (transumbilical en-
doscopic surgery). The current literature on the use of these
techniques in Gynecology is still rather limited.
Transvaginal endoscopy includes the procedure of ovarian
capsule drilling and reconstructive ovarian surgery in endome-
triosis. Transvaginal ovarian drilling in women with PCOS is an
easy intervention with minimal trauma and low morbidity
that is performed in a watery environment. Ovarian electrocau-
tery has been stated to be second-line treatment for PCOS
(Thessaloniki ESHRE/ASRM Sponsored PCOS Consensus
WorkshopGroup, 2008). The clinical outcome after ovarian dril-
ling depends on the number of punctures per ovary. Based on
animal studies evaluating tissue damage after ovarian drilling,
the optimal case is to perform theprocedure via transvaginal hy-
drolaparoscopy (THL) with a bipolar diathermy needle making
10–15 punctures with 70 w for 10 s (Amer et al., 2003).
The laparoscopic removal of endometriomas is associated
with a signiﬁcant decrease in residual ovarian volume, which
may result in diminished ovarian reserve and function; this
does not happen in the case of ovarian dermoids (Hirokawa
et al., 2011).
The myometrial junctional zone is structurally and func-
tionally different from the outer endometrium and plays an
important role in reproduction, especially in gamete transpor-
tation and implantation. During placentation, trophoblast in-
vasion is preceded by decidual remodeling of endometrium
and the junctional zone is essential for implantation. For
this reason, evaluation of the uterus should include visualiza-
tion of the myometrial junctional zone, considering that
subtle lesions, such as adenomyosis, may be detected by mag-
netic resonance imaging. A novel approach for the investiga-
tion of the junctional zone could be performed with an
ultrasound guided myometrial biopsy during diagnostic hys-
teroscopy using the spirotome, a device speciﬁcally designed
for endometrial sampling.
The Medical Treatment of Endometriosis
The main principles of treatment for Endometriosis-
Associated Chronic Pelvic Pain are that: (i) initial surgery is
more effective than medical treatment, but multiple surgeries
should be avoided; (ii) all hormone-altering medications have
equivalent efﬁcacy but have different side effects; (iii) 3
months of initial treatment is as effective as 6 months; (iv)
3 months re-treatment is as effective as 6 months of initial
treatment; (v) shorter courses of medication have fewer side
effects including bone loss; (vi) the ideal add-back regimen
after GnRH agonist therapy has not been established; (vii)
oral contraceptives are effective for maintenance in patients;
(viii) different medical therapies can be used sequentially in
the same patient; (ix) since hysterectomy and oophorectomy
frequently may become necessary, attention to fertility issues
is mandatory and (x) biopsychosocial issues are a critical
component of effective care.
For the treatment of infertility in endometriosis, data are
insufﬁcient to recommend a speciﬁc strategy such as ovarianVOL. 98 NO. 6 / DECEMBER 2012suppression (Allen et al., 2005) or ovarian suppression and
surgery (Hughes et al., 2007). Conversely, controlled ovarian
stimulation has been reported to be effective in minimal/mild
endometriosis before laparoscopy (Yap et al., 2004).
A new staging system has been developed, the endometri-
osis fertility index, which is a simple, robust and validated
clinical tool that predicts pregnancy rates for patients follow-
ing surgical staging of endometriosis (Adamson and Pasta,
2010). Its use is especially valuable in developing treatment
plans for infertile endometriosis patients.
The effect of endometriosis on the IVF outcome is contro-
versial with several confounding factors typically making it
difﬁcult to draw conclusions. However, there are consistent
data showing that IVF is a valid alternative for women with
stage III/IV endometriosis who (i) fail to conceive following
conservative surgery or because of advancing reproductive
age; (ii) have compromised tubal function in the presence of
male factor infertility and/or (iii) have failed other treatments.
No data support an effect of the stage of endometriosis on the
IVF outcomewith the exception of an overall lower pregnancy
rate in endometriosis. Similar statements can be made for the
presence of endometriomas. Regarding the role of ovarian
suppression before IVF, there are no RCTs with adequate con-
trols, but some evidence suggests improved pregnancy rates
when suppression precedes IVF (Sallam et al., 2006).
Several different innovations are also under study to im-
prove the IVF outcomes.
One of these, lipiodol, has been shown to improve live
birth rates slightly in women with endometriosis who are at-
tempting natural conception (Johnson et al., 2004).
UNEXPLAINED INFERTILITY
This section deals with treatment options for couples with
‘unexplained infertility’. While various treatments tend to
be empiric, there has been a vast contrast in the approaches
used in Europe and in the United States.
Over the past two decades the overall success of IVF has
increased signiﬁcantly, while results of IUI have remained
stable and have been associated with an unpredictable occur-
rence of multiple pregnancies (Reindollar et al., 2010). More
recently, the cost-effectiveness of prescribing gonadotro-
phin/IUI has been questioned. Two large NIH- sponsored trials
have been completed, one in women younger than 40 years
and the other in women older than 38 years. The ﬁrst trial,
known as the FASTT trial, compared the standard IUI treat-
ment approach (three cycles of CC/IUI followed by three cy-
cles FSH/IUI and then with up to six IVF cycles) with an
accelerated treatment that omitted FSH/IUI cycles. The ﬁnd-
ings showed that the accelerated approach to IVF resulted
in a shorter time to pregnancy with an equivalent cumulative
percentage of pregnancies occurring in less treatment cycles
and with cost savings, suggesting that FSH/IUI was of no
added value (Reindollar et al., 2010). According to the FASTT
hypothesis, an accelerated approach to IVF (that eliminates
FSH/IUI, but starts with CC/IUI) represents the best treatment
option. The reason to start with CC/IUI is because, with nor-
mal stimulation and no cancelation of cycles, it allows the
most fertile couples with the highest chance for multiple preg-
nancies to become pregnant before IVF is attempted.1383
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ported the hypothesis that immediate treatment with two
cycles of IVF for older women (38–42 years) results in signif-
icantly higher pregnancy and live birth rates compared with
two cycles of either CC/IUI or FSH/IUI (Reindollar et al., 2011).
In other studies, mostly European, observational arms
with no treatment had been included, and these studies
suggested that initial expectant management provides con-
siderable cost savings, without jeopardizing the time to
pregnancy or chances of pregnancy. The use of IUI with
controlled ovarian stimulation provided similar pregnancy
results to the expectant management group, suggesting
that expectant management for 6 months is justiﬁed in these
couples (Steures et al., 2006). A commentary on this ap-
proach is that the controlled stimulation in these trials was
milder, with many cycles being canceled because of multiple
follicular recruitment, thereby resulting in pregnancy rates
not statistically different from natural cycles with timed
intercourse.
In patients with unexplained or mild male subfertility, it
has been suggested that one cycle of IVF-eSET as ﬁrst-line
treatment seems to be as effective as three stimulated IUI
cycles (Custers et al., 2012). However, there are data to suggest
that use of clomifene alone or IUI alone is unlikely to offer su-
perior live birth rates compared with expectant management
(Bhattacharya et al., 2008). In the view of the presenter re-
garding the European experience, initial expectant manage-
ment provides considerable savings without jeopardizing
time to pregnancy or the chance of pregnancy.
ENVIRONMENT AND REPRODUCTION
This section encompassed a review of known and emerging
data regarding the epidemiology of reproduction, the role of
culture media, whether there are perinatal risks with various
interventions and the potential effects of environmental
toxins.
Epidemiology of Reproduction
A declining age at menarche has been observed in industrial-
ized European countries, and in the USA, over the last 100
years. Puberty in girls is now 5 years earlier than historically
reported (Parent et al., 2003). This change could have an effect
on the risk of reproductive cancer, age of menopause and
reproductive senescence. There is an association between
obesity and PCOS, and environmental exposures may in-
crease the risk of endometriosis and ﬁbroids.
Despite the methods available for family planning, 50%
of pregnancies currently are unplanned (Finer and
Henshaw, 2006).
The concept of natural fecundity in recent years has
changed, especially when considering the inﬂuence of popu-
lation density, environmental exposure, ethnicity, obesity
and social constructs. Similarly, factors like nutrition, various
exposures and concomitant illnesses could affect the repro-
ductive life span.
Unexplained infertility is one of the most intriguing chal-
lenges for reproductive medicine, often involving undiag-
nosed issues of ovarian reserve and male factor, or failure
of implantation.1384Some ART-related risk factors are modiﬁable, such as
time to conception, ovulation induction, an altered endocrine
environment at implantation, incubation and manipulation
of gametes and embryos including the use of ICSI and ex-
tended culture.
Generally speaking, the possible effect of ART on the
childhood outcome is of great concern. Although the etiology
of various morbidities is not completely understood, it is be-
lieved that the underlying infertility, time to conception and
ovulation induction (independent of IVF) all are contributing
factors. However, some data also support a negative contribu-
tion of laboratory factors such as extended embryo culture
(Kansal Kalra et al., 2010) and of the hormonal environment
at the time of transfer (Kansal Kalra et al., 2011). Very recent
data also suggest that the rate of HCG rise is faster following
the transfer of cryopreserved embryos, that the HCG rise is
positively associated with birthweight but not with gesta-
tional age at delivery and that subjects with a faster HCG
rise were less likely to have an infant of low birthweight
(Morse et al., 2011).
The possibility exists that adult diseases have a develop-
mental origin. If the epigenome is altered by ART and/or by
the environment, then the corresponding effect could start
as early as conception or implantation. Co-morbidities such
as PCOS, endometriosis and obesity may affect pregnancy
(Barnhart et al., 2002). PCOS elevates the risk for gestational
diabetes mellitus, pre-eclampsia and possibly adult cardio-
vascular disease.
There is little understanding of the high rate of early fetal
loss in humans and, for this reason, diagnosis and manage-
ment of women with ectopic pregnancy and miscarriage
have not changed dramatically in decades. There is a strong
need to identify and validate molecular markers speciﬁc for
ectopic pregnancy, miscarriage and women who need surgi-
cal treatment.
During the late reproductive years, decreased ovarian re-
serve could represent a window into premature aging. There
are reports about the presence of altered telomerase activity
in gametes and of greater risk of cardiovascular disease, hy-
pertension, altered metabolism and cancer. Male reproductive
senescence is associated with erectile dysfunction and appar-
ently with the risk of autism in children.
A ﬁnal consideration about premature ovarian failure,
primary ovarian insufﬁciency and premature menopause
and the possible association with Fragile X premutation, sug-
gests that genetic markers could predict fecundity in the nor-
mal population as well as in response to therapy.
Culture Media
Commercially available culture media for clinical IVF contain
between 11 andmore than 30 different components plus some
type of protein supplement such as human serum albumin,
synthetic serum substitute or plasmanate. Due to the limited
access to human oocytes/zygotes for research, it is clear
that the optimal formulation for ART media does not exist.
When designing a culture medium, zygote/embryo physiol-
ogy has been studied, and research with animal embryos,
and analyses of the constituents of the human fallopian
tube and uterus have been undertaken. Then modiﬁcationsVOL. 98 NO. 6 / DECEMBER 2012
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in vitro compared with in vivo. Animal models, mostly mice,
have provided much of our understanding of early embryo
physiology under culture conditions (Biggers et al., 1971). Us-
ing simplex optimization in which media components were
systematically tested at speciﬁc concentrations and combina-
tions, a superior medium for mouse embryo culture was de-
veloped (Lawitts and Biggers, 1991). This medium has since
been modiﬁed for use in clinical IVF and is one of the most
popular ‘single-step medium’ used today for culturing human
embryos from the pronucleate stage on Day 1 through to the
blastocyst stage on Day 5. In contrast, the design of sequential
media originated from the observation that zygotes and em-
bryos change metabolically and uptake/secrete differently
during different stages of development (Gardner et al.,
1996). However, no convincing data have proven that se-
quential media, two-step media (used in sequence from Day
1 to Day 3, and then from Day 3 to Day 5) support embryo
quality better than modern monophasic and one-step media.
Surprisingly, there are large differences between formula-
tions and usually only marginal scientiﬁc data supporting
more recent formulations. Some culture media contain
growth factors like insulin, and one medium is supplemented
with GM-CSF (granulocyte-macrophage colony-stimulating
factor). Besides any possible advantage, insulin induces ab-
normal methylation patterns in mice embryos, while GM-
CSF, by reducing apoptosis, could have an effect on the
epigenome.
Culture media can inﬂuence the growth rate and implan-
tation of human embryos, but it is totally unknown whether
a faster growth is synonymous with better growth. In a com-
parison of two media, the one promoting faster growth re-
sulted in pregnancies where HCG rose earlier and with
higher levels, and the children were 200 g heavier at birth
compared with the other medium (Dumoulin et al., 2010;
Nelissen et al., 2011). Although there was no appropriate con-
trol, the dissimilarity in birthweights suggests that different
formulations may have different effects on the epigenome
of the embryo. However, at least one other study failed to
show any signiﬁcant association between type of culture me-
dium and birthweight (Eaton et al., 2012).
With these concepts in mind, ESHRE set up a working
group on culture media whose aim was to focus on the rela-
tionship between culture media (and culture conditions) and
the phenotype of the offspring. The working group positions
were: (i) companies should disclose the composition and pref-
erably the formulation of each medium that is used clinically,
(ii) new formulations should have a scientiﬁc foundation, (iii)
a standard minimum QC certiﬁcate should be shared by all
companies that should use the same SOPs, (iv) a more relevant
test than the mouse embryo assay should be designed and (v)
great caution should be taken regarding the addition of
growth factors or hormones to culture media until more is
known about possible effects on the epigenome.
Perinatal Outcome
The analysis of more than 30 years of IVF has revealed that
there are short-term consequences of ART. There is increased
morbidity for children conceived with IVF, with less thanVOL. 98 NO. 6 / DECEMBER 201250% of pregnancies having a full-term infant without any
complications. The disease process appears to be altered
both in the child (low birthweight noted even when not pre-
mature) and in the mother (Shevell et al., 2005). Poor peri-
natal outcome and more episodes of long hospitalization
have been reported in children born after ovulation induc-
tion, suggesting that either ovulation induction treatment
or the reasons for the treatment increase the risk of health
problems in early childhood (Klemetti, 2010). Several ques-
tions are still unanswered about the clinical implications
of the short-term outcomes and possible long-term conse-
quences. Also unknown is how IVF may confer risk. Does
ART result in abnormal placentation or is this inherently
due to infertility or subfertility (Raatikainen et al., 2010)?
When trying to determine the effect of IVF on the risk of
perinatal morbidity, multiple births are a major variable,
but after adjusting for multiple births, ovarian hyperstimula-
tion syndrome and suboptimal endometrial development ap-
pear to be signiﬁcant factors.
It is unclear why frozen embryo transfer reduces mor-
bidity (Kansal Kalra et al., 2011) and how extended culture
increases morbidity as preliminary evidence tends to
suggest.
The subspecialty of reproductive endocrinology and in-
fertility needs to take the lead in addressing the issues related
to the risks in ART for which an important step is to change
the informed consent process. Minimizing multiple preg-
nancy is the foremost goal, as well as understanding what
part of ART is associated with adverse outcomes. To be
avoided is (i) underestimating the magnitude of this issue in
the eyes of the public by simply blaming it on the disease or
the patient, (ii) let another discipline (or the government) dic-
tate standard of care, (iii) use unproven technology without
careful consideration and full disclosure and (iv) dismiss the
risk to infertile patients.
Environmental Toxins
The hypothesis that toxicants could negatively affect repro-
duction arose many years ago when endocrine disrupting
compounds (EDCs) were suspected to have an impact
(Colburn, 1995) and have a role in the decrease in sperm
count over the past 50 years (Carlsen et al., 1992), acting
as estrogen disruptors (Sharpe and Sakkebaek, 1993). Poten-
tial sites of disruption are spread throughout the whole re-
productive system, from hormone receptors, to germ cell
development, the process of fertilization and embryo devel-
opment by affecting genetic and epi- genetic mechanisms,
implantation and pregnancy. Consequently, disorders may
occur in females: reproductive tract abnormalities, preco-
cious puberty, premature thelarche, infertility, endometri-
osis, PCOS and breast abnormalities/cancer. In males,
reproductive tract disorders such as hypospadias and crypt-
orchidism, abnormal semen indices, infertility, testicular and
prostate cancer have been observed leading to what is
known as ‘testicular dysgenesis syndrome’. The factors
inﬂuencing the outcome are age at exposure, latency from
exposure, importance of mixtures and non-traditional
dose-response dynamics. The effects may be trans-
generational including epigenetic changes.1385
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affecting reproduction are complex. For example, the sug-
gested decline in sperm quality during the past decade is
not supported by convincing evidence (Axelsson et al., 2011).
Chemicals implicated as EDCs are heavy metals, such as
lead, agricultural chemicals like DBCP (1,2-dibromo-
3-chloropropane) and vinclozalin, and industrial chemicals,
such as phthalates and BPA (Bisphenol A).
Lead can be found in plastics, mirrors, paint, transmis-
sions and gasoline, soil and ceramics. Children are the most
vulnerable and contact usually happens through inhalation
and ingestion. Animal studies revealed that in males it causes
decreased levels of testosterone, LH and FSH; defective sper-
matogenesis and sperm function as well as epigenetic
changes (Sokol, 2002).
DBCB has been proven to cause irreversible sperm toxic-
ity (Whorton et al., 1977) and is currently prohibited in Europe
and the USA. Vinclozalin in animal studies showed serious ef-
fects in males including androgen receptor disruption, unde-
scended testes, hypospadias, delayed puberty and
transgenerational effects (Anway and Skinner, 2006).
Phthalates are ubiquitous (personal care products, food
packing and processing materials, building materials and
medication coating) and have been shown in animals to cause
cryptorchidism, oligospermia and reduced anal-genital dis-
tance. Clinical studies performed in the USA reported higher
urine levels and lower sperm count, while a study in newborns
found a possible increased incidence of hypospadias and
cryptorchidism and possibly reduced anal-genital distance
(Swan et al., 2005).
BPA in male animals has been associated with decreased
anal genital distance and prostate abnormalities, while in fe-
males there were changes in mammary glands and early pu-
berty. Clinical studies do not provide deﬁnitive evidence, but
there is a possible association in males with erectile dysfunc-
tion and in females with PCOS.
In summary, exposure to chemicals is increasing and an-
imal studies support the hypothesis that some chemicals dis-
rupt reproduction. Although some clinical data suggest that
EDCs disrupt the reproductive system, a cause and effect con-
nection has not yet been clearly established and, therefore,
further clinical studies are needed. However, based on the
available evidence both the EU and the USA issued regula-
tions of chemical exposure: lead was regulated in EU and
the USA; DBCP was banned in many countries, but not all;
phthalates were banned from cosmetics and baby toys in
the EU, while in the USA only limited amounts were allowed
in toys; BPAwas banned from baby bottles in the EU, the USA
and Canada.
THE CORE OF ART: THE PROCESS OF IVF AND
EMBRYO TRANSFER
With the constant improvement of laboratory procedures and
culture systems, the rates of implantation have increased sig-
niﬁcantly leading to a reconsideration of the number of em-
bryos to transfer, with the speciﬁc aim of decreasing the
incidence of high-order multiple gestations. With the aware-
ness that morphology alone does not reﬂect the physiology of1386the embryo, non-invasive assays have been proposed to iden-
tify markers of viability in individual embryos. Included in
this discussion are sections on the gametes, embryos, the
day of transfer and implantation as well as data on oocyte
cryopreservation and preimplantation genetic screening.The Gametes
Unfortunately, the assessment of oocyte viability remains
rather superﬁcial and a general morphological evaluation
leads to the discarding only of those oocytes with nuclear im-
maturity or with signiﬁcant degeneration or gross abnormal-
ities. Thus, the great majority of metaphase II oocytes are
inseminated, and the selection of the embryo destined for
transfer is entirely based on its morphology and growth irre-
spective of the quality of the corresponding oocyte.
There are data which show that the analysis of the bire-
fringence properties of the meiotic spindle and the zona pel-
lucida are indicative of good health of the oocyte (Magli et al.,
2011; Montag et al., 2011), although there is no agreement re-
garding its clinical applicability (Petersen et al., 2009). Novel
data are coming from the application of studying gene ex-
pression from cumulus cells, using microarrays, as bio-
markers for oocyte viability (Menezo et al., 2010; Assidi
et al., 2011). The metabolomic proﬁling of oocyte spent cul-
ture media by mass spectroscopy has found differences re-
lated to oocyte maturation, embryo development and
implantation success (Nagy et al., 2009). Similar results
have been shown by the measurement of oocyte oxygen con-
sumption (Tejera et al., 2011). These data are very preliminary,
but demonstrate an increasing interest toward the oocyte as
the cell that determines embryo development and viability.
Signiﬁcant progress has also beenmade recently in deﬁn-
ing the role of the sperm cell in guiding the oocyte to resume
meiosis and undergo fertilization and cleavage. Following
progesterone release by the cumulus cells, a progesterone-
induced Ca2þ inﬂux in spermatozoa triggers hyper- activa-
tion, the acrosome reaction and chemotaxis toward the
oocyte (Lishko et al., 2011). Once released into the oocyte,
the sperm PLC-zeta factor mobilizes the Ca2þ signal that in-
duces egg activation and embryo development with a tight
association reported between the type of calcium oscillations
and embryo development (Ajduk et al., 2011). Accordingly,
abnormalities in PLC-zeta negatively affect fertilization rates
and possibly embryo development, conﬁrming the key role of
this factor in triggering oocyte activation. This ﬁnding sug-
gests that certain types of infertility could be caused by failure
of the sperm cell to properly activate the oocyte due to a defec-
tive PLC-zeta factor (Heytens et al., 2009; Kashir et al., 2011).
Once entered into the oocyte, sperm chromatin and DNA
integrity are necessary to ensure normal embryo development
(Barratt et al., 2010). Although it is now clear that DNA dam-
age in spermatozoa has a negative inﬂuence on blastocyst de-
velopment and the ICSI outcome, there is a strong need to
standardize the speciﬁc tests used to quantify the extent of
DNA damage (Barratt et al., 2010). Similarly, centrosome in-
tegrity is critical for successful fertilization and embryo de-
velopment, and new data indicate that the replacement of
defective centrosomes, which are responsible for speciﬁcVOL. 98 NO. 6 / DECEMBER 2012
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somes can restore normal functionality (Schatten and Sun,
2009).
A great deal of research has recently emerged providing
evidence regarding novel aspects in sperm cell DNA structure,
namely the presence of epigenetic information in the form of
post-translational modiﬁcations (e.g. histones), which may
impart speciﬁc imprints especially in developmentally impor-
tant genes and passing on the genetic information to the oo-
cyte (Hammoud et al., 2009). Sperm from infertile patients
show different patterns of epigenetic marking compared
with fertile men, particularly at certain imprinted and devel-
opmental loci (Hammoud et al., 2011).
The sperm cell also contains various forms of RNA, e.g.
mRNA, miRNA, siRNA (Cappallo-Obermann et al., 2011;
Krawetz et al., 2011) as well as more than 2000 proteins
with unknown roles.
Following gamete interaction by conventional IVF or
ICSI, even in cases with apparently normal oocytes and sper-
matozoa, fertilization failure occurs 20–30% of the time. The
incidence of total fertilization failure (TFF) after conventional
IVF using sperm of normal quality has been reported to range
from 5% (Bhattacharya et al., 2001) to as high as 15–20%
(Barlow et al., 1990; Liu and Baker, 2000). While ICSI has
overcome many fertilization problems, it does not completely
eliminate TFF. In a randomized clinical trial comparing out-
comes after ICSI or IVF for cases of non-male factor infertil-
ity, Bhattacharya et al. (2001) documented a TFF rate of 2
versus 5% for ICSI and IVF, respectively. Indeed, several large
studies using ICSI for a variety of infertility diagnoses re-
ported TFF at rates of 1.3% in 1779 cycles (Esfandiari et al.,
2005) and 3% in 2732 cycles (Liu et al., 1995).
The speciﬁc causes are unknown, but failure in most ICSI
cycles is ascribed to defective activation, while with conven-
tional IVF, lack of sperm penetration is the leading reason of
failure. In an analysis of speciﬁc cases of failures, oocyte mat-
uration arrest was associated with highly abnormal spindle/
chromosomal structures (Heindryckx et al., 2011). In some
cases of oocyte spontaneous activation or activation failure,
experiments with heterologous gametes may help determine
the contributing factor (Combelles et al., 2010, 2011).
The etiology of fertilization failure is complex and
heterogeneous and requires more speciﬁc research.
The Embryo
The improvement of culture systems has provided the possi-
bility of extending embryo cultures to Days 5 and 6, making
the day of transfer a ﬂexible choice. The reasons supporting
extended cultures to Days 5 and 6 are (i) the identiﬁcation
of those embryos capable of developing to the blastocyst
stage in vitro, (ii) a modest selection against aneuploidy and
(iii) a uterine environment that is likely more favorable for
blastocyst transfer (Fanchin et al., 2001). Potential downsides
are (i) increased risk of having no transfer when applied in un-
selected patients (Glujovsky et al., 2012), (ii) increased occur-
rence of monozygotic/monochorionic twins, especially after
ICSI (Skiadas et al., 2008) (iii) fewer embryos available for
cryopreservation (Glujovsky et al., 2012) and (iv) the risk
that prolonging duration of culture could cause epigeneticVOL. 98 NO. 6 / DECEMBER 2012disorders, as suggested by animal and perinatal outcome
data (Kallen et al., 2010; Park et al., 2011).
A special advantage associated with blastocyst transfer is
related to the practice of PGD/PGS, both when the biopsy is
performed at earlier stages giving more time for the analysis
before blastocyst transfers, and when it is done from trophec-
toderm cells, a strategy that seems to be very promising in
terms of the accuracy of the results with improved implanta-
tion rates (Schoolcraft et al., 2010).
It is clear that the day of transfer should be individual-
ized for each patient (Glujovsky et al., 2012). The capacity to
identify an embryo that develops into a viable blastocyst
requires a robust scoring system. Besides the classical mor-
phological scoring criteria, novel tools come from the obser-
vation of dynamic parameters on Day 2 that can predict
with high accuracy blastocyst formation. It has also been
shown that imaging phenotypes reﬂect the molecular pro-
gram of the embryo, where individual blastomeres develop
autonomously towards embryo genomic activation (Wong
et al., 2010). Prospective trials are now warranted to deter-
mine whether such time-lapse imaging improves implanta-
tion rates compared with current standard morphological
assessment.
The procedure of embryo transfer is critical in determin-
ing successful implantation and a skillful operator and the use
of a soft catheter are associated with the best results (Yao
et al., 2009).
There is a general consensus that elective Single Blasto-
cyst Transfer (eSBT) should be indicated in young, good-
prognosis patients with good quality embryos thus promoting
a reduced twin rate without decreasing the chances of preg-
nancy. In addition, the high survival rate of cryopreserved
blastocysts greatly contributes to good cumulative pregnancy
rates (Mesut et al., 2011).
The maternal and neonatal risks of multiple gestations
and deliveries associated with their socioeconomic costs, pro-
moted the adoption of advocating elective single-embryo
transfer (eSET) by some countries, particularly in Northern
Europe. After almost a decade of this experience, the general-
ized use of eSET in a fresh cycle combined with the subse-
quent transfer of a frozen embryo provides outcomes that
are similar to one fresh cycle with dual embryo transfer
(DET) (McLernon et al., 2010). The main difference resides
in the incidence of multiple live birth rates that drops signif-
icantly from 22–29% after DET to 1% in eSET (McLernon
et al., 2010).
The measure of treatment success is crucial to the accep-
tance of eSET, for which the focus needs to be shifted away
from the results of a single fresh cycle to results of cumulative
cycles. In this case, eSET matches or outperforms DET
(Practice Committee of Society for Assisted Reproductive
Technology; and Practice Committee of American Society
for Reproductive Medicine, 2012). As a prerequisite to this
strategy, the cryopreservation program must be efﬁcient
and reliable. Patients' characteristics should be carefully eval-
uated when deciding on the transfer policy, since poor prog-
nosis factors such as advanced female age, poor embryo
quality and some infertility factors may dictate the need for
DET (Lawlor and Nelson, 2012).1387
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rates in the US are higher than in those countries with a greater
percentage of eSET cycles. These differences cannot be ex-
plained by the larger number of embryos transferred
(Gleicher et al., 2007). However because of the expectation
of couples in the US for higher pregnancy rates and the fact
that most cycles have to be paid for by the couple, there has
been some reluctance in adopting a strict eSET program
(Practice Committee of Society for Assisted Reproductive
Technology; and Practice Committee of American Society
for Reproductive Medicine, 2012). Nevertheless there is keen
awareness that eSET should be seriously considered in good
prognosis patients with good embryo quality (Practice
Committee of Society for Assisted Reproductive
Technology; and Practice Committee of American Society
for Reproductive Medicine, 2012). Not to be forgotten is pa-
tient autonomy, and the couples' choice. A survey a few years
ago reported that many couples strongly favor twin pregnan-
cies (Practice Committee of American Society for
Reproductive Medicine, 2012). However, proper education
and information given to patients signiﬁcantly changed this
position (Newton et al., 2007).
Implantation
Successful implantation requires that the transferred embryo
be viable and that the uterus is receptive. In this regard it was
reafﬁrmed that both embryologists and clinicians contribute
signiﬁcantly to this end. A successful IVF program requires
the update of professionals on new advances and knowledge
as well as high laboratory QC/QA standards.
Unfortunately a high proportion of transferred embryos
fail to implant, and there is a group of patients where implan-
tation failure occurs repeatedly even under optimal condi-
tions. Several strategies have been adopted to overcome
recurrent implantation failure (RIF), addressing both the em-
bryo, using techniques like assisted hatching, and the endo-
metrium by intensifying the investigation of the female
reproductive tract. The administration of intravenous immu-
noglobulins (IVIG) in women suspected of having an immu-
nological cause of RIF did not improve the live birth rates
when compared with placebo (Stephenson and Fluker,
2000). Similarly, in the presence of ACA (anti-cardiolipin an-
tibodies), the use of heparin and aspirin showed no beneﬁt
(Stern et al., 2003). Attempts of administering steroids
(Boomsma et al., 2007) or low-dose aspirin (Gelbaya et al.,
2007) were also negative.
In a novel approach, repeated endometrial biopsies in the
cycle immediately preceding IVF treatment has been shown
signiﬁcantly to increase implantation, pregnancy and live
birth rates in women who had at least one previous IVF failure
(Barash et al., 2003). A positive outcome was also found after
the intrauterine administration of autologous PBMCs (periph-
eral blood mononuclear cells) (Yoshioka et al., 2006) espe-
cially when pretreated with CRH (corticotropin-releasing
hormone) that acts by regulating apoptosis of activated T-
lymphocytes at the implantation site (Makrigiannakis et al.,
2001). As a proposed mechanism of action, CRH added to
primary cultures of PBMCs signiﬁcantly increases IL-6 release
(Th2-type immunity) and decreases IFN-g (Thl-type1388immunity) levels in a dose dependent manner. In this way,
CRH induces stromal decidualiza- tion and potentiates the de-
cidualizing effect of progesterone (Zoumakis et al., 2000).
More work is still needed in this challenging area.
Oocyte Cryopreservation
Oocyte cryopreservation has been used for i) fertility preser-
vation for medical or social reasons, ii) use of cryo-banked
oocytes for egg donation, iii) storage of spare oocytes avoid-
ing the production of supernumerary embryos, iv) storage of
oocytes in cases of no sperm availability, and v) aspiration of
excess oocytes in IUI cycles.
Several factors inﬂuence the clinical efﬁciency of oocyte
cryopreservation including female age (which might be more
important than in fresh cycles), quality of oocytes, and, most
importantly, the technique used - slow freezing or vitriﬁca-
tion. The critical evaluation of results should be based on
the implantation rate, calculated on the basis of thawed/
warmed oocytes (Gook and Edgar, 2007).
Widespread use of oocyte cryopreservation began with
the introduction of vitriﬁcation after the birth of the ﬁrst
baby from warmed oocytes (Kuleshova et al., 1999). The
most recent publications demonstrate a performance that is
comparable to that obtained with fresh oocytes in young
women (Rienzi et al., 2010; Cobo et al., 2011) and possibly
a superiority over the slow-freezing method (Smith et al.,
2010; Cobo and Daz 2011). Nevertheless, proper randomized
controlled trials are still lacking and when comparisons are
made taking into consideration the number of implantations
per thawed/warmed oocyte, the two techniques have gener-
ally shown similar performance (Kim et al., 2010; Bianchi
et al., 2012). In addition, it must be considered that the great
majority of data on oocyte vitriﬁcation derive from oocytes
from fertile patients as used in donor egg programs, and not
from infertile women, particularly those who are older.
Neonatal data on more than 900 children demonstrate no
increase in spontaneous miscarriage, chromosomal anoma-
lies or birth defects (Noyes et al., 2009). These data are consid-
ered by many as a good argument to remove the label of
‘experimental’ from the technique of oocyte cryopreservation.
Nevertheless, a meticulous follow-up of pregnancies, espe-
cially from infertile patients and on the health of children
are considered to be mandatory to ﬁnally prove the safety
of the technique.
Preimplantation Genetic Screening (PGS)
To date, randomized controlled trials have not shown that
PGS by FISH on blastomeres from cleavage-stage embryo
has improved the live birth rate compared with a control
group (Mastenbroek et al., 2011). Possible reasons could be
that i) the biopsied blastomere is not truly representative of
the embryo at the 8-cell stage because of mosaicism; ii) the bi-
opsy procedure itself might cause harm and negatively inﬂu-
ence the developmental potential of the embryo; iii) not all
chromosomes were tested by FISH; and iv) the contribution
of aneuploidy to implantation failure may be overestimated.
Therefore, two possible alternatives were proposed, namely
trophectoderm biopsy and polar body biopsy for the analysis
of all chromosomes (Bisignano et al., 2011; Handyside, 2011).VOL. 98 NO. 6 / DECEMBER 2012
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abnormalities can be studied without touching the future em-
bryo, but possible disadvantages are the limited amount of
time available for this analysis, the presence of mosaicism, al-
though at a level lower than at the 8-cell stage, and the fact
that the trophectoderm might not be representative of the in-
ner cell mass. For the polar body biopsy, advantages are that
polar bodies are external to the embryonic mass and do not
exhibit mosaicism. However, this approach only permits the
testing of maternal chromosomes and does not evaluate mi-
totic errors, including the possible correction of meiotic errors
following mitosis.
When deciding to perform PGS, two aspects play an im-
portant role, namely the validation of the protocol to be used
for the chromosomal analysis and the safety of the biopsy
procedure.
ESHRE recently organized a pilot study to verify the fea-
sibility and reliability of full-karyotype testing on polar bod-
ies by CGH array technology with conﬁrmation of results on
the corresponding oocytes. It was shown that the analysis of
both polar bodies could be completed within a time period
that allows for fresh transfer with a reliable identiﬁcation of
the chromosomal status in about 90% of biopsy attempts,
and a concordance of results between polar body and oocyte
of 94% (Geraedts et al., 2011; Magli et al., 2011). From a bio-
logical point of view, the study of meiosis demonstrated that
MII anomalies predominate over MI, with chromatid predivi-
sion being the most frequent mechanism of aneuploidy-
causing mechanism, and chromosome losses prevailing over
chromosome gains (Fragouli and Wells, 2011; Handyside
et al., 2012).
The results of the pilot study promoted the organization
of a multicentre, randomized double-blind controlled trial
with an intention-to-treat analysis including womenwith ad-
vanced maternal age. The trial, called the ESHRE Study into
The Evaluation of oocyte Euploidy by Microarray analysis
(ESTEEM), has two primary aims i) to assess the predictive
value of having no euploid oocytes in future ART cycles;
and ii) to improve live birth rates. The results are expected
within two years.
An alternative approach proposed is the use of single nu-
cleotide polymorphism (SNP) microarrays whose validity has
been tested in single cells from cell lines, with a demonstrated
98.6% accuracy for overall assignment of aneuploidy status
(Treff et al., 2010a). An experimental comparison with FISH
based aneuploidy screening showed that SNP microarray is
signiﬁcantly more reliable for providing interpretable results
(Treff et al., 2010b), and can be achieved in only four hours
(Treff et al., 2012). In this way, the transfer can be done in
a fresh cycle, although the process of vitriﬁcation does not
seem to impair the implantation of euploid blastocysts
(Schoolcraft et al., 2011).
To investigate whether the procedure of biopsy may be
critical for embryo selection or what stage is optimum, data
on DNA ﬁngerprinting that permits the tracking of the im-
planted embryo suggest that blastomere biopsy decreases im-
plantation, whereas this does not happen with trophectoderm
biopsy (Treff et al., 2011a,b). In addition, it has been shown
that the chromosomal analysis on blastocysts has anVOL. 98 NO. 6 / DECEMBER 2012excellent negative and positive predictive value with the
eventual clinical outcome (Scott et al., 2012).
OVARIAN CANCER AND MENOPAUSE
Reproductive medicine encompasses concerns regarding can-
cer as well as the management of menopause. In this section,
theories of ovarian carcinogenesis are explored as well as the
‘timing’ hypothesis regarding the use of hormones in women
after menopause.
Ovarian Cancer: The Incessant Menstruation
Hypothesis
Epithelial ovarian cancers are the most lethal form of gonadal
malignancies for which routine screening has no effect on
mortality. The most common form is serous carcinoma, fol-
lowed by endometrioid, clear cell, and mucinous carcinoma.
The vast majority of ovarian cancers arise from non ovarian
cells; serous carcinomas from tubal epithelial cells, and endo-
metrioid cell carcinoma from endometrial cells.
It has been suggested that retrograde menstruation may
have a role in carcinogenesis through the generation of
reactive oxygen species (ROS) which results from the action
of free iron derived from the lysis of reﬂuxed erythrocytes
in the peritoneal cavity (Toyokuni, 2009). ROS promote the
activation of Ml-macrophages, which favor tumorgenesis
by inducing epithelial cell transformation sustained by M2-
macrophages (Mantovani and Sica, 2010). Reﬂuxed blood
collects in the pouch of Douglas, close to the distal tube,
and chronically exposes the epithelium of ﬁmbria to heme,
iron, and macrophages, possibly contributing to the develop-
ment of serous carcinoma. Similarly, the high concentration
of free iron in endo- metriotic cysts could cause carcinogen-
esis through persistent oxidative stress (Yamaguchi et al.,
2008).
The number of lifetime menstruations, pelvic endometri-
osis and the use of the IUD are considered risk factors for
ovarian cancers, whilst hormonal contraception and tubal li-
gation are protective factors (Collaborative Group on
Epidemiological Studies of Ovarian Cancer, 2008).
Bilateral salpigoophorectomy results in a reduced risk of
ovarian cancer (Domchek et al., 2010), but a higher incidence
of coronary heart disease (Parker et al., 2009). A possible
strategy could be hysterectomy with ovarian preservation
(Moorman et al., 2011) or the post-reproductive removal of
fallopian tubes (Dietl et al., 2011). Despite some evidence
supporting the tubal hypothesis, some concern and doubt re-
main (Collins et al., 2011). At the present time, a preventative
strategy should be the use of hormonal contraception for pro-
longed periods of time, especially in women with endometri-
osis. In addition, bilateral salpingectomy may be considered
in women not desirous of future pregnancies.
Menopause: The Timing Hypothesis
Several RCTs in the past l0 years showed increased cardiovas-
cular (CV) risk in women initiating hormones at regular doses,
up to 20 years after menopause. The putative protective ef-
fects of hormonal therapy (HT) were detected in observational
studies in women initiating HT close to menopause; similar1389
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initiation of HT may be critical in determining risks and
beneﬁts.
Clinical and animal studies have demonstrated that
early and continued estrogen treatment has beneﬁcial ef-
fects that can arrest atherosclerotic lesion development.
However, after a vascular plaque has been established,
which occurs with natural aging or in an accelerated fashion
with risk factors such as hypercholesterolemia, the vascular
effects of estrogen are no longer beneﬁcial (Mendelsohn and
Karas, 2005). In addition, when initiated late in the athero-
sclerotic process, HT could have adverse effects, potentially
destabilizing existing plaques and triggering a coronary
event. Oral estrogens increase the expression of matrix met-
alloproteinase (MMPs) that are produced by the inﬂamma-
tory cells in the atheroma.
It is postulated that standard doses of oral estrogens may
cause early cardiovascular events in older women through
up-regulation of MMPs, disruption of the ﬁbrous cap, and
subsequent rupture of plaque. In recent RCTs, administration
of conjugated equine estrogens (CEE) for up to 6 years pro-
vided no protection against myocardial infarction (MI) or cor-
onary death in generally healthy post-menopausal women
who were in the wide age span of 50–79 years, but there
was a statistical reduction in coronary heart disease with
CEE among women in the 50 to 59 year old age group (Hsia
et al., 2006).
Also in the WHI, women 50 to 59 years old receiving es-
trogen had less calciﬁed-plaque burden in their coronary ar-
teries compared with placebo (Manson et al., 2007). A more
recent case control study also suggested that early initiation
of HT reduced the prevalence of abnormal coronary angio-
grams (Shufelt et al., 2011).
In a series of meta-analyses HT was found to reduce CHD
events as well as mortality in younger post-menopausal
women, whilst in older women, HT initially increases and
then decreases risk over time (Salpeter et al., 2006, 2009).
However, the ‘timing’ hypothesis has not been tested in
a RCT as hard end-points of MI or CVD mortality are not pos-
sible in a young healthy population. Use of ‘intermediate’
end-points with a high correlation to CHD have been pro-
posed, and have been incorporated into the design of on- go-
ing RCTs, namely KEEPS and ELITE.
Estrogens have several important effects on the brain be-
ing neuroprotective and neurotrophic, and act especially on
neurotransmitters, glial cells, proteins- amyloid, Tau and
apo E, and regulate organizational activity (Henderson, 1997).
Many observational studies and meta-analyses agree that
the use of estrogens in mid-life reduces a woman's risk of sub-
sequent dementia, whereas HT initiation in late life could
have deleterious effects (Whitmer et al., 2011) as was also
shown in a substudy of WHI. In cases with Alzheimer's dis-
ease, estrogens seem to have an effect on cognition that is
most apparent on tasks of semantic memory.
In conclusion, RCT data regarding the ‘timing’ hypothesis
are sorely needed. KEEPS and ELITE will be available shortly,
but in the meantime young, healthy, symptomatic women
near the onset of menopause should not be fearful of HT in
terms of CV or dementia risk. Nevertheless, it is unlikely1390that we will ever see an HT indication for either coronary dis-
ease or Alzheimer's risk.
CONCLUSION
Many diverse topics were discussed and debated at this ﬁrst-
of- a- kindmeeting of ASRM and ESHRE. In the ﬁnal analysis,
we wished to convey current best practices in reproductive
medicine, realizing that there are differences in approaches
in the US and Europe. It is hoped that the summary above cap-
tures at least some of the valuable exchange of ideas which
will foster better reproductive healthcare.
PRESENTERS AT BEST PRACTICES OF ASRM
AND ESHRE
David Adamson (USA), Kurt Barnhart (USA), Chris Barratt
(UK), Marcelle Cedars (USA), Catherine Combelles (USA), Gio-
vanni Coticchio (IT), Pier Giorgio Crosignani (IT), Bart Fauser
(NL), Anna P Ferraretti (IT), Joep Geraedts (NL), Stephan
Gordts (Belgium), Richard S Legro (USA), Kersti Lundin (Swe-
den), Roger A Lobo (USA), M Cristina Magli (IT), Antonis
Makrigiannakis (GR), Catherine Racowsky (USA), Richard
Reindollar (USA), Laura Rienzi (IT), Glenn Schattman (USA),
Rebecca Sokol (USA), Arne Sunde (Norway), Basil Tarlatzis
(GR), Nathan Treff (USA), Fulco Van der Veen (NL), Anna
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